

UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023

FOR

**ETHOS PHARMACEUTICAL ETHICS AND
COMPLIANCE LIMITED**

The Carley Partnership
St James's House
8 Overcliffe
Gravesend
Kent
DA11 0HJ

	Page
Company Information	1
Balance Sheet	2
Notes to the Financial Statements	4

**ETHOS PHARMACEUTICAL ETHICS AND
COMPLIANCE LIMITED**

**COMPANY INFORMATION
FOR THE YEAR ENDED 31 MARCH 2023**

DIRECTORS:

Dr N B Broughton
Mrs L.S. Sharp

REGISTERED OFFICE:

St James's House
8 Overcliffe
Gravesend
Kent
DA11 0HJ

REGISTERED NUMBER:

11368668 (England and Wales)

ACCOUNTANTS:

The Carley Partnership
St James's House
8 Overcliffe
Gravesend
Kent
DA11 0HJ

**ETHOS PHARMACEUTICAL ETHICS AND
COMPLIANCE LIMITED (REGISTERED NUMBER: 11368668)**

**BALANCE SHEET
31 MARCH 2023**

	Notes	2023 £	£	2022 £	£
FIXED ASSETS					
Intangible assets	4		167,813		-
Tangible assets	5		<u>7,069</u>		<u>1,963</u>
			174,882		1,963
CURRENT ASSETS					
Debtors	6	70,607		130,601	
Cash at bank and in hand		<u>52,923</u>		<u>60,701</u>	
		123,530		191,302	
CREDITORS					
Amounts falling due within one year	7	<u>162,633</u>		<u>119,290</u>	
NET CURRENT (LIABILITIES)/ASSETS			<u>(39,103)</u>		<u>72,012</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			135,779		73,975
CREDITORS					
Amounts falling due after more than one year	8		(15,982)		(21,047)
PROVISIONS FOR LIABILITIES			<u>(1,767)</u>		<u>(373)</u>
NET ASSETS			<u>118,030</u>		<u>52,555</u>
CAPITAL AND RESERVES					
Called up share capital			100		100
Retained earnings			<u>117,930</u>		<u>52,455</u>
SHAREHOLDERS' FUNDS			<u>118,030</u>		<u>52,555</u>

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

**BALANCE SHEET - continued
31 MARCH 2023**

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 7 September 2023 and were signed on its behalf by:

Mrs L.S. Sharp - Director

Dr N B Broughton - Director

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023**

1. STATUTORY INFORMATION

Ethos Pharmaceutical Ethics And Compliance Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Intangible assets

Development expenditure is written off to the profit and loss account in the year in which it is incurred, unless the directors are satisfied as to the technical, commercial and financial viability on specific projects. In this situation, the expenditure is capitalised and amortised using the straight-line method over the period during which the company is expected to benefit.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - Straight line over 3 years

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2022 - 1) .

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2023**

4. INTANGIBLE FIXED ASSETS

	Other intangible assets £
COST	
Additions	169,938
At 31 March 2023	<u>169,938</u>
AMORTISATION	
Charge for year	2,125
At 31 March 2023	<u>2,125</u>
NET BOOK VALUE	
At 31 March 2023	<u>167,813</u>

5. TANGIBLE FIXED ASSETS

	Plant and machinery etc £
COST	
At 1 April 2022	3,848
Additions	7,879
Disposals	(935)
At 31 March 2023	<u>10,792</u>
DEPRECIATION	
At 1 April 2022	1,885
Charge for year	2,565
Eliminated on disposal	(727)
At 31 March 2023	<u>3,723</u>
NET BOOK VALUE	
At 31 March 2023	<u>7,069</u>
At 31 March 2022	<u>1,963</u>

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2023 £	2022 £
Trade debtors	47,561	125,236
Other debtors	<u>23,046</u>	<u>5,365</u>
	<u>70,607</u>	<u>130,601</u>

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2023**

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2023	2022
	£	£
Bank loans and overdrafts	5,066	4,941
Trade creditors	12,160	15,071
Amounts owed to group undertakings	94,973	39,600
Amounts owed to associates	23,760	7,920
Taxation and social security	19,019	50,364
Other creditors	7,655	1,394
	<u>162,633</u>	<u>119,290</u>

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

	2023	2022
	£	£
Bank loans	<u>15,982</u>	<u>21,047</u>

9. RELATED PARTY DISCLOSURES

As at the balance sheet date, the company owed its parent company, Green Bear Medical Limited, £94,973 (2022: £39,600). The company also owed The Sharp Consulting Group Limited, an associated company, £23,760 (2022: £7,920).

10. ULTIMATE CONTROLLING PARTY

The ultimate parent company and controlling party is Green Bear Medical Limited, a company registered in England and Wales.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.